Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

Active:	Yes
Cancer Type:	Unknown Primary Uterine Cancer	NCT ID:	NCT06486441
Trial Phases:	Phase III	Protocol IDs:	GS-US-682-6769 (primary) NCI-2024-05881 2024-511957-23 APGOT-EN2 ENGOT-en26 GOG-3104
Eligibility:	18 Years and older, Female	Study Type:	Treatment
Study Sponsor:	Gilead
NCI Full Details:	http://clinicaltrials.gov/show/NCT06486441

Summary

The goal of this clinical study is to find out how the study drug, sacituzumab govitecan
(SG) works in participants with endometrial cancer who have received prior treatment with
platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice
(TPC).

The primary objectives of this study are to evaluate the effect of SG compared to TPC on
progression-free survival (PFS) as assessed by blinded independent central review (BICR)
and overall survival (OS).

Treatment Sites in Georgia

Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
225 Candler Drive
Savannah, GA 31405
912-819-5778
www.sjchs.org

Doctors:

Sarah Elizabeth Gill MD

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.